Amgen Inc. (AMGN)
| Market Cap | 236.38B +54.7% |
| Revenue (ttm) | 38.10B +9.1% |
| Net Income | 8.74B +32.1% |
| EPS | 16.09 +31.6% |
| Shares Out | 540.63M |
| PE Ratio | 27.17 |
| Forward PE | 18.64 |
| Dividend | $10.08 (2.31%) |
| Ex-Dividend Date | Aug 21, 2026 |
| Volume | 1,656,100 |
| Open | 437.03 |
| Previous Close | 444.12 |
| Day's Range | 435.00 - 441.85 |
| 52-Week Range | 269.77 - 447.03 |
| Beta | 0.43 |
| Analysts | Buy |
| Price Target | 388.48 (-11.15%) |
| Earnings Date | Aug 4, 2026 |
About AMGN
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascul... [Read more]
Financial Performance
In 2025, Amgen's revenue was $36.75 billion, an increase of 9.95% compared to the previous year's $33.42 billion. Earnings were $7.71 billion, an increase of 88.53%.
Financial StatementsAnalyst Summary
According to 34 analysts, the average rating for AMGN stock is "Buy." The 12-month stock price target is $388.48, which is a decrease of -11.15% from the latest price.
News
AMGEN TO PRESENT AT THE 2026 WELLS FARGO HEALTHCARE CONFERENCE
THOUSAND OAKS, Calif., Sept. 2, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will present at the 2026 Wells Fargo Healthcare Conference at 11:00 a.m.
UK regulator suspends Amgen's Tavneos for new patients over unreliable data
Britain's medicines regulator on Tuesday suspended the use and sale of Amgen's rare-disease drug, Tavneos, to new patients, saying the main study supporting its approval was unreliable.
Trump administration to announce drug pricing deals
U.S. President Donald Trump is expected to announce a new round of drug-pricing agreements on Monday, a White House official said, part of a push to make healthcare more affordable for Americans.
AMGEN'S REPATHA® REDUCES RISK OF DEATH IN PATIENTS AT HIGH RISK FOR A FIRST HEART ATTACK OR STROKE
Repatha is the First and Only PCSK9 Inhibitor Shown to Lower the Risk of Dying from All Causes, Including Cardiovascular Events, in High-Risk Primary Prevention Patients in a Phase 3 Trial Separate Gl...
TEZSPIRE® DEMONSTRATES POSITIVE PHASE 3 RESULTS IN EOSINOPHILIC ESOPHAGITIS ACROSS BOTH CO-PRIMARY AND ALL KEY SECONDARY ENDPOINTS
Statistically Significant and Clinically Meaningful Disease and Symptom Improvements Compared to Placebo Maintained Through Week 52 Efficacy in a Third Epithelial-Driven Inflammatory Disease Supports ...
White House to announce new drug pricing deals with biotechs, Bloomberg News reports
U.S. President Donald Trump's administration is planning to announce a new round of drug-pricing agreements with midsize biotech companies on Monday, Bloomberg News reported on Wednesday, c...
Expert explains why healthcare is a top-performing sector
Apollon Wealth Management CIO Eric Sterner discusses how technology is driving gains in the healthcare sector on ‘The Claman Countdown.' #fox #media #breakingnews #us #usa #new #news #breaking #foxbus...
Amgen Earnings Call Transcript: Q2 2026
Q2 2026 revenues rose 10% year-over-year to over $10 billion, driven by strong growth across six key product areas, with 22 products posting double-digit sales gains. Guidance for 2026 was raised, reflecting robust execution, expanding pipeline, and continued investment in innovation.
Amgen Earnings release: Q2 2026
Amgen released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
Amgen Slides: Q2 2026
Amgen has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 4, 2026.
Amgen Quarterly report: Q2 2026
Amgen has published its Q2 2026 quarterly earnings report on August 4, 2026.
Amgen Lifts Outlook on Strong Drug Sales, to End Early Development of Obesity Treatment
The biotechnology company now expects full-year revenue between $38.2 billion and $39.4 billion, but said it was halting the development of a potential obesity treatment currently in a phase 1 study.
Amgen second-quarter sales rise 9%, profit tops Street view
Amgen on Tuesday reported second-quarter sales rose 9%, driven by demand for cholesterol drug Repatha, bone drug Evenity and medications for rare diseases, as the company continues to develop experim...
AMGEN REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS
THOUSAND OAKS, Calif., Aug. 4, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced financial results for the second quarter of 2026.
Amgen discloses data breach, says patient information was stolen
Drugmaker Amgen suffered a cybersecurity breach where hackers stole company data and patient health information from cloud storage systems run by third-party providers, it said in a regu...
AMGEN ANNOUNCES 2026 THIRD QUARTER DIVIDEND
THOUSAND OAKS, Calif., July 30, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.52 per share dividend for the third quarter of 2026.
AMGEN ANNOUNCES WEBCAST OF 2026 SECOND QUARTER FINANCIAL RESULTS
THOUSAND OAKS, Calif., July 28, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its second quarter 2026 financial results on Tuesday, August 4, 2026, after the close of th...
Amgen submits new data to challenge FDA's proposal to withdraw Tavneos
Amgen said on Friday it submitted new evidence to the FDA on July 23 as it seeks a hearing to challenge the proposed withdrawal of its rare-disease drug Tavneos from the U.S. market.
Amgen settles shareholder lawsuit claiming it hid $10.7 billion tax bill
Amgen reached a $74 million settlement of a lawsuit accusing the biotechnology company of waiting too long to disclose that it might owe the Internal Revenue Service $10.7 billion for underreporting...
Judge blocks Colorado's first-of-its-kind price cap on Amgen's Enbrel
A federal judge on Wednesday blocked Colorado from capping the price of Amgen's blockbuster arthritis drug Enbrel, a first-of-its-kind move by a U.S. state.
Medical journal retracts paper on Amgen's Tavneos drug trial after FDA findings
The New England Journal of Medicine on Monday retracted an article on a pivotal clinical trial that supported approval of Amgen's rare-disease drug, citing concerns that patient outcome data were alt...
European Regulator Calls for Amgen's Tavneos to Have Authorization Revoked
The committee is recommending that no new patients start treatment with Tavneos and that existing patients be switched to suitable alternatives.
EMA recommends revoking marketing authorisation for Amgen's rare-disease drug
The European Medicines Agency on Friday recommended revoking the marketing authorisation for Amgen's rare autoimmune disease drug, Tavneos, citing a lack of benefits that outweigh its risks.
Harbour BioMed Secures Landmark Victory in U.S. Patent Infringement Case Against Amgen, Reshaping the Global Antibody Patent Landscape
The case, originally filed in 2021 by Harbour Antibodies, asserted that Amgen and Teneobio (an Amgen subsidiary) infringed patents protecting Harbour's groundbreaking antibody discovery platform Delaw...